

Will G Dixon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/421940/publications.pdf>

Version: 2024-02-01

172
papers

10,071
citations

44042

48
h-index

37183

96
g-index

194
all docs

194
docs citations

194
times ranked

11517
citing authors

#	ARTICLE	IF	CITATIONS
1	Using patient-generated health data in clinical practice: How timing influences its function in rheumatology outpatient consultations. <i>Patient Education and Counseling</i> , 2022, 105, 625-631.	1.0	6
2	Sleep Disturbance and Quality of Life in Rheumatoid Arthritis: Prospective mHealth Study. <i>Journal of Medical Internet Research</i> , 2022, 24, e32825.	2.1	13
3	Heterogeneity in the association between weather and pain severity among patients with chronic pain: a Bayesian multilevel regression analysis. <i>Pain Reports</i> , 2022, 7, e963.	1.4	9
4	Using patient-reported data from a smartphone app to capture and characterize real-time patient-reported flares in rheumatoid arthritis. <i>Rheumatology Advances in Practice</i> , 2022, 6, rkac021.	0.3	5
5	The Influence of Chronic Pain on Social Care Service Use in the UK. <i>Journal of Long-Term Care</i> , 2022, .	0.5	0
6	Findability of UK health datasets available for research: a mixed methods study. <i>BMJ Health and Care Informatics</i> , 2022, 29, e100325.	1.4	1
7	Investigating characteristics of idiopathic inflammatory myopathy flares using daily symptom data collected via a smartphone app. <i>Rheumatology</i> , 2022, 61, 4845-4854.	0.9	4
8	Better digital health data should be the foundation to transform outpatient consultations for people living with long-term conditions. <i>Journal of the Royal Society of Medicine</i> , 2022, , 014107682210890.	1.1	2
9	The impact of moderator by confounder interactions in the assessment of treatment effect modification: a simulation study. <i>BMC Medical Research Methodology</i> , 2022, 22, 88.	1.4	3
10	P066â€fCOVID Voices: co-produced research to explore the shielding experiences of people with inflammatory musculoskeletal disease. <i>Rheumatology</i> , 2022, 61, .	0.9	0
11	P068â€fMonitoring of methotrexate blood toxicity during the COVID-19 pandemic for patients with rheumatoid arthritis: data from the Greater Manchester Care Record. <i>Rheumatology</i> , 2022, 61, .	0.9	0
12	P078â€fInternational impact of a co-produced training video: self-examination of tender and swollen joints for people with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	0
13	P097â€fUsing a smartphone app to better detect and characterise real-time patient-reported flares in rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	0
14	Adoption of Digital Pain Manikins for Research Data Collection: A Systematic Review. <i>Studies in Health Technology and Informatics</i> , 2022, , .	0.2	0
15	Glucocorticoid use is associated with an increased risk of hypertension. <i>Rheumatology</i> , 2021, 60, 132-139.	0.9	22
16	Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. <i>Lancet Rheumatology</i> , The, 2021, 3, e19-e27.	2.2	49
17	Implementing disruptive technological change in UK healthcare: exploring development of a smart phone app for remote patient monitoring as a boundary object using qualitative methods. <i>Journal of Health Organization and Management</i> , 2021, 35, 141-159.	0.6	3
18	Digital manikins to selfâ€report pain on a smartphone: A systematic review of mobile apps. <i>European Journal of Pain</i> , 2021, 25, 327-338.	1.4	19

#	ARTICLE	IF	CITATIONS
19	Public Perspectives of Using Social Media Data to Improve Adverse Drug Reaction Reporting: A Mixed-Methods Study. <i>Drug Safety</i> , 2021, 44, 553-564.	1.4	8
20	Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients? Authors' reply. <i>Lancet Rheumatology</i> , The, 2021, 3, e172-e173.	2.2	1
21	P156 Myositis flares are associated with reduced work productivity and fewer hours worked: illustration of the future potential of digital healthcare solutions in rheumatic diseases. <i>Rheumatology</i> , 2021, 60, .	0.9	0
22	P094 Incidence of clinically diagnosed Paget's disease of bone: evidence of a continuing decline. <i>Rheumatology</i> , 2021, 60, .	0.9	0
23	Incidence of Paget's disease of bone in the UK: evidence of a continuing decline. <i>Rheumatology</i> , 2021, 60, 5668-5676.	0.9	6
24	The use of narrative electronic prescribing instructions in pharmacoepidemiology: A scoping review for the International Society for Pharmacoepidemiology. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1281-1292.	0.9	3
25	Opioid prescribing among new users for non-cancer pain in the USA, Canada, UK, and Taiwan: A population-based cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003829.	3.9	13
26	Understanding the Predictors of Missing Location Data to Inform Smartphone Study Design: Observational Study. <i>JMIR MHealth and UHealth</i> , 2021, 9, e28857.	1.8	4
27	Co-designing new tools for collecting, analysing and presenting patient experience data in NHS services: working in partnership with patients and carers. <i>Research Involvement and Engagement</i> , 2021, 7, 85.	1.1	5
28	Engagement with consumer smartwatches for tracking symptoms of individuals living with multiple long-term conditions (multimorbidity): A longitudinal observational study. <i>Journal of Multimorbidity and Comorbidity</i> , 2021, 11, 263355652110627.	0.8	4
29	Perceptions of opioid use and impact on quality of life in patients with musculoskeletal conditions within online health community forums. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab078.	0.3	0
30	How Do Glucocorticoids Used in Rheumatic Disease Affect Body Weight? A Narrative Review of the Evidence. <i>Arthritis Care and Research</i> , 2020, 72, 489-497.	1.5	7
31	Providing "the bigger picture": benefits and feasibility of integrating remote monitoring from smartphones into the electronic health record. <i>Rheumatology</i> , 2020, 59, 367-378.	0.9	75
32	O18 National variation and factors associated with long-term opioid use for non-cancer pain in the first year of use. <i>Rheumatology</i> , 2020, 59, .	0.9	0
33	Patient insights on living with idiopathic inflammatory myopathy and the limitations of disease activity measurement methods – a qualitative study. <i>BMC Rheumatology</i> , 2020, 4, 47.	0.6	9
34	Remote symptom monitoring integrated into electronic health records: A systematic review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 1752-1763.	2.2	41
35	Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: A retrospective cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003270.	3.9	81
36	Incorporating patient generated health data into pharmacoepidemiological research. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1540-1549.	0.9	13

#	ARTICLE	IF	CITATIONS
37	P59 Social care use in people with chronic pain. <i>Rheumatology</i> , 2020, 59, .	0.9	0
38	Multinational Investigation of Fracture Risk with Antidepressant Use by Class, Drug, and Indication. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1494-1503.	1.3	16
39	Are weather conditions associated with chronic musculoskeletal pain? Review of results and methodologies. <i>Pain</i> , 2020, 161, 668-683.	2.0	23
40	Patient discussions of glucocorticoid-related side effects within an online health community forum. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1121-1122.	0.5	6
41	Pneumonia vaccination timing in relation to starting conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1665-1666.	0.5	2
42	The effect of glucocorticoid therapy on mortality in patients with rheumatoid arthritis and concomitant type II diabetes: a retrospective cohort study. <i>BMC Rheumatology</i> , 2020, 4, 4.	0.6	6
43	Weather Patterns Associated with Pain in Chronic-Pain Sufferers. <i>Bulletin of the American Meteorological Society</i> , 2020, 101, E555-E566.	1.7	10
44	Modeling of cumulative effects of time-varying drug exposures on within-subject changes in a continuous outcome. <i>Statistical Methods in Medical Research</i> , 2020, 29, 2554-2568.	0.7	8
45	Progress in Characterizing the Human Exposome: a Key Step for Precision Medicine. <i>Yearbook of Medical Informatics</i> , 2020, 29, 115-120.	0.8	9
46	Engagement and Participant Experiences With Consumer Smartwatches for Health Research: Longitudinal, Observational Feasibility Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e14368.	1.8	43
47	Digital methods to enhance the usefulness of patient experience data in services for long-term conditions: the DEPEND mixed-methods study. <i>Health Services and Delivery Research</i> , 2020, 8, 1-128.	1.4	3
48	Development of a Mobile Digital Manikin to Measure Pain Location and Intensity. <i>Studies in Health Technology and Informatics</i> , 2020, 270, 946-950.	0.2	5
49	Patient discussions of glucocorticoid-related side effects within an online community health forum. <i>Clinical Medicine</i> , 2019, 19, 91-91.	0.8	1
50	How the weather affects the pain of citizen scientists using a smartphone app. <i>Npj Digital Medicine</i> , 2019, 2, 105.	5.7	49
51	A review of accelerometer-derived physical activity in the idiopathic inflammatory myopathies. <i>BMC Rheumatology</i> , 2019, 3, 41.	0.6	18
52	O17 Changing trends and prescribing patterns in opioid treated primary care patients with non-cancer pain over a 10-year period. <i>Rheumatology</i> , 2019, 58, .	0.9	0
53	O19 The association of biologic drug-levels with infection risk: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). <i>Rheumatology</i> , 2019, 58, .	0.9	0
54	P01 Incidence of juvenile idiopathic arthritis in the United Kingdom: estimates from a national primary care dataset. <i>Rheumatology</i> , 2019, 58, .	0.9	3

#	ARTICLE	IF	CITATIONS
55	Multinational comparison of new antidepressant use in older adults: a cohort study. <i>BMJ Open</i> , 2019, 9, e027663.	0.8	28
56	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1160-1166.	0.5	34
57	Maximizing Engagement in Mobile Health Studies. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 159-172.	0.8	108
58	Exposure measurement error when assessing current glucocorticoid use using UK primary care electronic prescription data. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 179-186.	0.9	13
59	Collecting Symptoms and Sensor Data With Consumer Smartwatches (the Knee OsteoArthritis, Linking) Tj ETQq1 1 0.784314 rgBT /Ov Protocols, 2019, 8, e10238.	0.5	18
60	Associations Between Engagement With an Online Health Community and Changes in Patient Activation and Health Care Utilization: Longitudinal Web-Based Survey. <i>Journal of Medical Internet Research</i> , 2019, 21, e13477.	2.1	18
61	Management of the Rheumatoid Arthritis Patient with Interstitial Lung Disease. <i>Respiratory Medicine</i> , 2018, , 121-161.	0.1	4
62	Assumptions made when preparing drug exposure data for analysis have an impact on results: unreported step in pharmacoepidemiology studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 781-788.	0.9	39
63	Using technology to support clinical care and research in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 276-281.	2.0	41
64	Quality of life, sleep and rheumatoid arthritis (QUASAR): a protocol for a prospective UK mHealth study to investigate the relationship between sleep and quality of life in adults with rheumatoid arthritis. <i>BMJ Open</i> , 2018, 8, e018752.	0.8	19
65	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 476-479.	0.5	47
66	Supplementing electronic health records through sample collection and patient diaries: A study set within a primary care research database. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 239-242.	0.9	6
67	Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. <i>Rheumatology</i> , 2018, 57, 1896-1907.	0.9	43
68	Response to: Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis by Kremer and Weinblatt. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e5-e5.	0.5	3
69	Representativeness of a digitally engaged population and a patient organisation population with rheumatoid arthritis and their willingness to participate in research: a cross-sectional study. <i>RMD Open</i> , 2018, 4, e000664.	1.8	7
70	Glucocorticoid-associated adrenal insufficiency in patients with rheumatoid arthritis: a study combining direct data collection with electronic health records. <i>Rheumatology</i> , 2018, 57, .	0.9	0
71	The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). <i>BMJ: British Medical Journal</i> , 2018, 363, k3532.	2.4	268
72	Ability to Predict New-Onset Psychological Distress Using Routinely Collected Health Data: A Population-Based Cohort Study of Women Diagnosed With Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1065-1073.	2.3	8

#	ARTICLE	IF	CITATIONS
73	Low salivary cortisol levels in patients with rheumatoid arthritis exposed to oral glucocorticoids: a cross-sectional study set within UK electronic health records. <i>RMD Open</i> , 2018, 4, e000700.	1.8	3
74	The limitations of using simple definitions of glucocorticoid exposure to predict fracture risk: A cohort study. <i>Bone</i> , 2018, 117, 83-90.	1.4	15
75	Comparative risk of respiratory depression in patients treated with opioids for non-malignant pain. <i>Rheumatology</i> , 2018, 57, .	0.9	0
76	Frequent discussion of insomnia and weight gain with glucocorticoid therapy: an analysis of Twitter posts. <i>Npj Digital Medicine</i> , 2018, 1, .	5.7	23
77	Consumer Smartwatches for Collecting Self-Report and Sensor Data: App Design and Engagement. <i>Studies in Health Technology and Informatics</i> , 2018, 247, 291-295.	0.2	3
78	Timing of glucocorticoid administration: a cross-sectional survey of glucocorticoid users in an online social network for health: Table 1. <i>Rheumatology</i> , 2017, 56, kew421.	0.9	2
79	Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 654-660.	0.5	122
80	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 386-391.	0.5	150
81	Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 497-503.	0.5	88
82	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. <i>RMD Open</i> , 2017, 3, e000314.	1.8	29
83	Patient perceptions of glucocorticoid side effects: a cross-sectional survey of users in an online health community. <i>BMJ Open</i> , 2017, 7, e014603.	0.8	45
84	Predictors of distress in female breast cancer survivors: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 229-245.	1.1	157
85	Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1509-1514.	0.5	29
86	Risks of smoking and benefits of smoking cessation on hospitalisations for cardiovascular events and respiratory infection in patients with rheumatoid arthritis: a retrospective cohort study using the Clinical Practice Research Datalink. <i>RMD Open</i> , 2017, 3, e000506.	1.8	11
87	Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2025-2030.	0.5	77
88	Sleep and cognitive performance: cross-sectional associations in the UK Biobank. <i>Sleep Medicine</i> , 2017, 38, 85-91.	0.8	102
89	A comparison of methods for estimating the temporal change in a continuous variable: Example of HbA1c in patients with diabetes. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1474-1482.	0.9	5
90	Opioids are not just an American problem. <i>BMJ: British Medical Journal</i> , 2017, 359, j5514.	2.4	8

#	ARTICLE	IF	CITATIONS
91	Response to: "Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?" by Nocturne et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e4-e4.	0.5	2
92	121. "PATIENTS' EXPERIENCES OF USING A SMARTPHONE APP FOR REMOTE MONITORING OF RHEUMATOID ARTHRITIS INTEGRATED INTO THE ELECTRONIC MEDICAL RECORD AND ITS IMPACT ON CONSULTATIONS. <i>Rheumatology</i> , 2017, 56, .	0.9	1
93	PAIN299. "ENGAGEMENT IN A UNITED KINGDOM SMARTPHONE STUDY EXAMINING THE ASSOCIATION BETWEEN WEATHER AND PAIN: PRELIMINARY RESULTS FROM CLOUDY WITH A CHANCE OF PAIN. <i>Rheumatology</i> , 2017, 56, .	0.9	0
94	Cloudy with a Chance of Pain: Engagement and Subsequent Attrition of Daily Data Entry in a Smartphone Pilot Study Tracking Weather, Disease Severity, and Physical Activity in Patients With Rheumatoid Arthritis. <i>JMIR MHealth and UHealth</i> , 2017, 5, e37.	1.8	60
95	Recruitment and Ongoing Engagement in a UK Smartphone Study Examining the Association Between Weather and Pain: Cohort Study. <i>JMIR MHealth and UHealth</i> , 2017, 5, e168.	1.8	41
96	Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1089-1098.	2.9	83
97	Defining Disease Phenotypes in Primary Care Electronic Health Records by a Machine Learning Approach: A Case Study in Identifying Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016, 11, e0154515.	1.1	64
98	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 965-973.	0.5	179
99	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 952-957.	0.5	258
100	Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 133-141.	1.6	126
101	A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. <i>Rheumatology</i> , 2016, 55, 2131-2137.	0.9	14
102	The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. <i>Rheumatology</i> , 2016, 55, 2033-2039.	0.9	67
103	Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1337-1345.	2.9	16
104	Smoking-Related Mortality in Patients With Early Rheumatoid Arthritis: A Retrospective Cohort Study Using the Clinical Practice Research Datalink. <i>Arthritis Care and Research</i> , 2016, 68, 1598-1606.	1.5	33
105	Genome-wide association analysis identifies novel loci for chronotype in 100,420 individuals from the UK Biobank. <i>Nature Communications</i> , 2016, 7, 10889.	5.8	237
106	Pharmacovigilance without borders: electronic health records in different countries can be used to address important methodological issues in estimating the risk of adverse events. <i>Journal of Clinical Epidemiology</i> , 2016, 77, 101-111.	2.4	6
107	Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. <i>Arthritis Research and Therapy</i> , 2016, 18, 251.	1.6	177
108	Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study. <i>European Journal of Epidemiology</i> , 2016, 31, 1045-1055.	2.5	42

#	ARTICLE	IF	CITATIONS
109	A review of the methods used to define glucocorticoid exposure and risk attribution when investigating the risk of fracture in a rheumatoid arthritis population. <i>Bone</i> , 2016, 90, 107-115.	1.4	12
110	Influenza and Pneumococcal Vaccination Uptake in Patients with Rheumatoid Arthritis Treated with Immunosuppressive Therapy in the UK: A Retrospective Cohort Study Using Data from the Clinical Practice Research Datalink. <i>PLoS ONE</i> , 2016, 11, e0153848.	1.1	46
111	The Association between Systemic Glucocorticoid Use and the Risk of Cataract and Glaucoma in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0166468.	1.1	38
112	Who Self-Weighs and What Do They Gain From It? A Retrospective Comparison Between Smart Scale Users and the General Population in England. <i>Journal of Medical Internet Research</i> , 2016, 18, e17.	2.1	16
113	Patient Perspectives on Sharing Anonymized Personal Health Data Using a Digital System for Dynamic Consent and Research Feedback: A Qualitative Study. <i>Journal of Medical Internet Research</i> , 2016, 18, e66.	2.1	139
114	Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. <i>RMD Open</i> , 2015, 1, e000019-e000019.	1.8	90
115	Modelling and extraction of variability in free-text medication prescriptions from an anonymised primary care electronic medical record research database. <i>BMC Medical Informatics and Decision Making</i> , 2015, 16, 18.	1.5	29
116	Consistency and Utility of Data Items Across European Rheumatoid Arthritis Clinical Cohorts and Registers. <i>Arthritis Care and Research</i> , 2015, 67, 1219-1229.	1.5	20
117	The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. <i>Rheumatology</i> , 2015, 54, 1074-1079.	0.9	22
118	Half of UK patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study. <i>Arthritis Research and Therapy</i> , 2015, 17, 375.	1.6	25
119	Rheumatoid arthritis: biological drugs and risk of infection. <i>Lancet</i> , The, 2015, 386, 224-225.	6.3	12
120	O10.â€fRisk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor-Î± Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2015, , .	0.9	0
121	Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1087-1093.	0.5	162
122	Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 290-305.	1.4	65
123	Problem list completeness in electronic health records: A multi-site study and assessment of success factors. <i>International Journal of Medical Informatics</i> , 2015, 84, 784-790.	1.6	121
124	Dynamic Consent: A Possible Solution to Improve Patient Confidence and Trust in How Electronic Patient Records Are Used in Medical Research. <i>JMIR Medical Informatics</i> , 2015, 3, e3.	1.3	95
125	P2.â€fIncidence and Severity of Myocardial Infarction in Subjects Receiving Anti-Tumour Necrosis Factor Drugs for Rheumatoid Arthritis: Results from Linking the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project. <i>Rheumatology</i> , 2014, 53, i34-i35.	0.9	4
126	O23.â€fThe Influence of Anti-TNF or Rituximab on Cancer Incidence in Patients with Rheumatoid Arthritis who Have Had a Prior Malignancy. <i>Rheumatology</i> , 2014, 53, i38-i38.	0.9	0

#	ARTICLE	IF	CITATIONS
127	39.â€fNon-Differential Reporting of Myocardial Infarction to a National Observational Drug Safety Study Using Linked Data: Linkage of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and the Myocardial Ischaemia National Audit Project. <i>Rheumatology</i> , 2014, 53, i70-i70.	0.9	0
128	Reconciling Healthcare Professional and Patient Perspectives in the Development of Disease Activity and Response Criteria in Connective Tissue Diseaseâ€related Interstitial Lung Diseases. <i>Journal of Rheumatology</i> , 2014, 41, 792-798.	1.0	43
129	The safety of biologic therapies in RA-associated interstitial lung disease. <i>Nature Reviews Rheumatology</i> , 2014, 10, 284-294.	3.5	74
130	Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 628-628.	0.5	18
131	A dynamic model of patient consent to sharing of medical record data. <i>BMJ, The</i> , 2014, 348, g1294-g1294.	3.0	19
132	A Threshold Hazard Model for Estimating Serious Infection Risk Following Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Patients. <i>Journal of Biopharmaceutical Statistics</i> , 2013, 23, 461-476.	0.4	3
133	Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1517-1523.	0.5	5
134	Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 229-234.	0.5	146
135	Consensus Statements for the Use of Administrative Health Data in Rheumatic Disease Research and Surveillance. <i>Journal of Rheumatology</i> , 2013, 40, 66-73.	1.0	32
136	Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. <i>Rheumatology</i> , 2013, 52, 91-98.	0.9	116
137	Unresolved Questions in Rheumatology: Motion for Debate: The Data Support Evidenceâ€Based Management Recommendations for Cardiovascular Disease in Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 1675-1683.	6.7	22
138	Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 461-462.	0.5	33
139	Understanding the side effects of glucocorticoid therapy: shining a light on a drug everyone thinks they know. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1761-1764.	0.5	26
140	The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 869-874.	0.5	107
141	Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested caseâ€control analysis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1128-1133.	0.5	273
142	Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. <i>Rheumatology</i> , 2011, 50, 124-131.	0.9	564
143	Influence of biological agents on cardiovascular disease in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 561-562.	0.5	6
144	Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1810-1814.	0.5	173

#	ARTICLE	IF	CITATIONS
145	The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. <i>Arthritis Research and Therapy</i> , 2011, 13, R139.	1.6	147
146	Looking beyond incidence in the relationship between anti-tumor necrosis factor therapy and malignancy. <i>Arthritis and Rheumatism</i> , 2011, 63, 1773-1775.	6.7	1
147	Bisphosphonates and esophageal cancer—a pathway through the confusion. <i>Nature Reviews Rheumatology</i> , 2011, 7, 369-372.	3.5	20
148	The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2011, 50, 1341-1342.	0.9	43
149	Is Anti-TNF Therapy Safer Than Previously Thought?. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2380-1.	3.8	10
150	The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 956-960.	0.5	116
151	Quantifying the longitudinal value of healthcare record collections for pharmacoepidemiology. <i>AMIA ... Annual Symposium proceedings</i> , 2011, 2011, 1318-25.	0.2	9
152	The Role of Anti-Tumor Necrosis Factor Receptor Agents in Cancer Survivors: Does the Risk Justify the Benefit?. <i>Seminars in Oncology</i> , 2010, 37, 11-19.	0.8	4
153	A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 40, 2-14.e1.	1.6	161
154	Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register. <i>Arthritis Care and Research</i> , 2010, 62, 755-763.	1.5	168
155	No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. <i>Arthritis and Rheumatism</i> , 2010, 62, 3145-3153.	6.7	72
156	Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1086-1091.	0.5	185
157	Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 522-528.	0.5	606
158	EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1596-1602.	0.5	87
159	Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor ± therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 209-215.	0.5	200
160	European biologics registers: methodology, selected results and perspectives. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1240-1246.	0.5	114
161	Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. <i>Rheumatology</i> , 2008, 47, 1000-1005.	0.9	67
162	The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2008, 20, 138-144.	2.0	105

#	ARTICLE	IF	CITATIONS
163	The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. <i>Current Opinion in Internal Medicine</i> , 2008, 7, 301-307.	1.5	1
164	What effects might anti-TNF α treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF α in cardiovascular pathophysiology. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1132-1136.	0.5	107
165	Serious infection following anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. <i>Arthritis and Rheumatism</i> , 2007, 56, 2896-2904.	6.7	292
166	Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register. <i>Arthritis and Rheumatism</i> , 2007, 56, 2905-2912.	6.7	522
167	Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al. <i>Arthritis Research and Therapy</i> , 2006, 8, 111.	1.6	44
168	Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. <i>Arthritis and Rheumatism</i> , 2006, 54, 2368-2376.	6.7	694
169	Does early rheumatoid arthritis exist?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 37-53.	1.4	25
170	Low grip strength is associated with bone mineral density and vertebral fracture in women. <i>Rheumatology</i> , 2005, 44, 642-646.	0.9	100
171	072. The Association Between Oral Glucocorticoid Therapy and Mortality in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study. <i>Rheumatology</i> , 0, , .	0.9	0
172	036. Prevalence of Adrenal Insufficiency Following Systemic Glucocorticoid Therapy Between 0 and 100%: A Systematic Review. <i>Rheumatology</i> , 0, , .	0.9	0